|
1
|
A JY, . Wang GJ, Sun JG, Gu YC, Wu MS and
Liu JH: Identification of phase I and phase II metabolites of
Guanfu base A hydrochloride in human urine. Eur J Drug Metab
Pharmacokinet. 28:265–272. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Berkenblit A and Cannistra SA: Advances in
the management of epithelial ovarian cancer. J Reprod Med.
50:426–438. 2005.PubMed/NCBI
|
|
3
|
Salom E, Almeida Z and Mirhashemi R:
Management of recurrent ovarian cancer: Evidence-based decisions.
Curr Opin Oncol. 14:519–527. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Agarwal R and Kaye SB: Ovarian cancer:
Strategies for overcoming resistance to chemotherapy. Nat Rev
Cancer. 3:502–516. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ozols RF, Bundy BN, Greer BE, Fowler JM,
Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM
and Baergen R: Gynecologic Oncology Group: Phase III trial of
carboplatin and paclitaxel compared with cisplatin and paclitaxel
in patients with optimally resected stage III ovarian cancer: A
Gynecologic Oncology Group study. J Clin Oncol. 21:3194–3200. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
du Bois A, Neijt JP and Thigpen JT: First
line chemotherapy with carboplatin plus paclitaxel in advanced
ovarian cancer-a new standard of care? Ann Oncol. 10 Suppl
1:S35–S41. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Biagi JJ and Eisenhauer EA: Systemic
treatment policies in ovarian cancer: The next 10 years. Int J
Gynecol Cancer. 13 Suppl 2:S231–S240. 2003. View Article : Google Scholar
|
|
8
|
Neijt JP, Engelholm SA, Tuxen MK, Sorensen
PG, Hansen M, Sessa C, de Swart CA, Hirsch FR, Lund B and van
Houwelingen HC: Exploratory phase III study of paclitaxel and
cisplatin versus paclitaxel and carboplatin in advanced ovarian
cancer. J Clin Oncol. 18:3084–3092. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kelland L: The resurgence of
platinum-based cancer chemotherapy. Nat Rev Cancer. 7:573–584.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Siddik ZH: Cisplatin: Mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Galluzzi L, Senovilla L, Vitale I, Michels
J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms
of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Greenlee RT, Hill-Harmon MB, Murray T and
Thun M: Cancer statistics, 2001. CA Cancer J Clin. 51:15–36. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gore ME, Fryatt I, Wiltshaw E and Dawson
T: Treatment of relapsed carcinoma of the ovary with cisplatin or
carboplatin following initial treatment with these compounds.
Gynecol Oncol. 36:207–211. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Malz M, Weber A, Singer S, Riehmer V,
Bissinger M, Riener MO, Longerich T, Soll C, Vogel A, Angel P, et
al: Overexpression of far upstream element binding proteins: A
mechanism regulating proliferation and migration in liver cancer
cells. Hepatology. 50:1130–1139. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rabenhorst U, Beinoraviciute-Kellner R,
Brezniceanu ML, Joos S, Devens F, Lichter P, Rieker RJ, Trojan J,
Chung HJ, Levens DL and Zörnig M: Overexpression of the far
upstream element binding protein 1 in hepatocellular carcinoma is
required for tumor growth. Hepatology. 50:1121–1129. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pénzváltó Z, Lánczky A, Lénárt J,
Meggyesházi N, Krenács T, Szoboszlai N, Denkert C, Pete I and
Győrffy B: MEK1 is associated with carboplatin resistance and is a
prognostic biomarker in epithelial ovarian cancer. BMC Cancer.
14:8372014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chung HJ and Levens D: c-myc expression:
keep the noise down! Mol Cells. 20:157–166. 2005.PubMed/NCBI
|
|
18
|
Duncan R, Bazar L, Michelotti G, Tomonaga
T, Krutzsch H, Avigan M and Levens D: A sequence-specific,
single-strand binding protein activates the far upstream element of
c-myc and defines a new DNA-binding motif. Genes Dev. 8:465–480.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu J, Chung HJ, Vogt M, Jin Y, Malide D,
He L, Dundr M and Levens D: JTV1 co-activates FBP to induce USP29
transcription and stabilize p53 in response to oxidative stress.
EMBO J. 30:846–858. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rabenhorst U, Thalheimer FB, Gerlach K,
Kijonka M, Böhm S, Krause DS, Vauti F, Arnold HH, Schroeder T,
Schnütgen F, et al: Single-Stranded DNA-Binding Transcriptional
Regulator FUBP1 Is Essential for Fetal and Adult Hematopoietic Stem
Cell Self-Renewal. Cell Rep. 11:1847–1855. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dixit U, Liu Z, Pandey AK, Kothari R and
Pandey VN: Fuse binding protein antagonizes the transcription
activity of tumor suppressor protein p53. BMC Cancer. 14:9252014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dixit U, Pandey AK, Liu Z, Kumar S,
Neiditch MB, Klein KM and Pandey VN: FUSE Binding Protein 1
facilitates persistent hepatitis C virus replication in hepatoma
cells by regulating tumor suppressor p53. J Virol. 89:7905–7921.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jameson GS, Petricoin EF, Sachdev J,
Liotta LA, Loesch DM, Anthony SP, Chadha MK, Wulfkuhle JD,
Gallagher RI, Reeder KA, et al: A pilot study utilizing multi-omic
molecular profiling to find potential targets and select
individualized treatments for patients with previously treated
metastatic breast cancer. Breast Cancer Res Treat. 147:579–588.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rask K, Nilsson A, Brännström M, Carlsson
P, Hellberg P, Janson PO, Hedin L and Sundfeldt K: Wnt-signalling
pathway in ovarian epithelial tumours: Increased expression of
beta-catenin and GSK3beta. Br J Cancer. 89:1298–1304. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Barghout SH, Zepeda N, Xu Z, Steed H, Lee
CH and Fu Y: Elevated β-catenin activity contributes to carboplatin
resistance in A2780cp ovarian cancer cells. Biochem Biophys Res
Commun. 468:173–178. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Murphy G and Nagase H: Localizing matrix
metalloproteinase activities in the pericellular environment. FEBS
J. 278:2–15. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zitka O, Kukacka J, Krizkova S, Huska D,
Adam V, Masarik M, Prusa R and Kizek R: Matrix metalloproteinases.
Curr Med Chem. 17:3751–3768. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Butler GS and Overall CM: Updated
biological roles for matrix metalloproteinases and new
‘intracellular’ substrates revealed by degradomics. Biochemistry.
48:10830–10845. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rodríguez D, Morrison CJ and Overall CM:
Matrix metalloproteinases: What do they not do? New substrates and
biological roles identified by murine models and proteomics.
Biochim Biophys Acta. 1803:39–54. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: Regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hadler-Olsen E, Fadnes B, Sylte I,
Uhlin-Hansen L and Winberg JO: Regulation of matrix
metalloproteinase activity in health and disease. FEBS J.
278:28–45. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang J and Chen QM: Far upstream element
binding protein 1: A commander of transcription, translation and
beyond. Oncogene. 32:2907–2916. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang YY, Gu XL, Wang C, Wang H, Ni QC,
Zhang CH, Yu XF, Yang LY, He ZX, Mao GX and Yang SY: The
far-upstream element-binding protein 2 is correlated with
proliferation and doxorubicin resistance in human breast cancer
cell lines. Tumour Biol. 37:9755–9769. 2016. View Article : Google Scholar : PubMed/NCBI
|
